key: cord-0928446-vn9ba1ku
authors: Virani, S.A.; Clarke, B.; Ducharme, A.; Ezekowitz, J.A.; Heckman, G.A.; McDonald, M.; Mielniczuk, L.M.; Swiggum, E.; Van Spall, H.G.C.; Zieroth, S.
title: Optimizing Access to Heart Failure Care in Canada during the COVID-19 Pandemic
date: 2020-05-13
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2020.05.009
sha: 658d2d43a59f3becfb8151b52e778d1caba6d4ef
doc_id: 928446
cord_uid: vn9ba1ku

The traditional model of heart failure (HF) care in Canada, which relies upon a multi-disciplinary team and clinic based care processes, has been undermined as a result of the COVID-19 pandemic. As the pandemic continues, we will be challenged to improve or maintain the health status of those with HF by optimizing guideline-directed care despite physical distancing constraints and a reduction in the healthcare workforce. This will require development of new strategies specifically targeted at decreasing the risk of decompensation and resultant HF hospitalization. As such, we must quickly pivot to the adoption and application of novel technologies and revise usual care models, processes, and workflow. The unprecedented COVID-19 crisis has delivered the Canadian HF community a burning platform for the design and implementation of innovative approaches to support the vulnerable population we serve; born out of necessity, we now have the opportunity to explore innovative approaches that may inform the future of HF care delivery in Canada. Herein, we provide perspectives from leadership within the Canadian Heart Failure Society (CHFS) on how to optimize HF care during the COVID-19 pandemic.

The COVID-19 pandemic has created urgency for design and implementation of innovative approaches to support ambulatory heart failure care delivery. Here we provide perspectives from leadership within the Canadian Heart Failure Society (CHFS) on how to optimize treatment for those living with heart failure within the broader context of COVID-19.

The traditional model of heart failure (HF) care in Canada, which relies upon a multidisciplinary team and clinic based care processes, has been undermined as a result of the COVID-19 pandemic. As the pandemic continues, we will be challenged to improve or maintain the health status of those with HF by optimizing guideline-directed care despite physical distancing constraints and a reduction in the healthcare workforce. This will require development of new strategies specifically targeted at decreasing the risk of decompensation and resultant HF hospitalization. As such, we must quickly pivot to the adoption and application of novel technologies and revise usual care models, processes, and workflow.

The unprecedented COVID-19 crisis has delivered the Canadian HF community a burning platform for the design and implementation of innovative approaches to support the vulnerable population we serve; born out of necessity, we now have the opportunity to explore innovative approaches that may inform the future of HF care delivery in Canada.

Herein, we provide perspectives from leadership within the Canadian Heart Failure Society (CHFS) on how to optimize HF care during the COVID-19 pandemic.

Like all chronic disease, heart failure (HF) management is predicated on comprehensive assessment of illness risk and severity. The overarching goal is to purposefully target patients for timely monitoring and intervention, so as to maintain or restore health stability. The challenge we face during a pandemic lies in how to deliver this best care in a virtual manner.

The Canadian Cardiovascular Society (CCS) Rapid Response Team has recommended a transition to telehealth and virtual health strategies to meet the needs of all patients with cardiovascular disease through the COVID-19 pandemic.

The CHFS and CCS Guidelines Panel have previously reported on patient and system related barriers to accessing HF care in Canada [1] , however reduced access to care must now be reconsidered with the lens of this pandemic. As such, we must deliberate on a number of additional issues (Table 1) .

This document provides pragmatic solutions to challenges arising from physical distancing measures and aims to develop an inventory of remote care approaches that can be applied in a bespoke manner to optimize a given patient's care. Our population of interest is two-fold and must include those whose care is currently coordinated through HF clinics (HFC) as well as those without established linkages to a HF care provider.

Recognizing that 'standard of care' is a fluid concept in the context of this pandemic, we offer practical and real-world guidance on four key topics related to the provision of HF services.

In response to this pandemic, HFC have uniquely adapted to their local environment and the population they serve, largely offering consultation through virtual or telehealth. Many still have the ability to see urgent patients in person, but are doing so in a very deliberate and organized manner focussing on the most vulnerable. Management of these patients is challenged by imperatives for physical distancing and/or reduced access to laboratory services.

The pursuit of pharmacotherapy optimization under these circumstances is subject to much debate. So-called, 'triple therapy' for HFrEF dramatically reduces mortality and hospitalization; in clinical trials, these effects are early and substantial. However, safely initiating and up-titrating these medications, as well as newer HFrEF therapies, may necessitate laboratory monitoring, which is challenged in the current environment.

In balancing these competing priorities, our approach is to be practical and pragmatic. Practitioners must be deliberate in their choices related to medication initiation/titration and must not be constrained by traditional HFrEF management algorithms -this might include treatment with a novel therapy earlier in the patient's disease course or in the absence of diagnostic imaging data ( Table 2) . Key enablers will include retaining a minimum health human resource compliment to support the virtual HFC's activity as well as extended public coverage for newer treatments.

The universal uptake of HF remote monitoring (RM) technologies has been limited in the absence of clear benefit from clinical trials [2] . Lessons learned from earlier efforts have helped provide the framework for an ideal intervention (Supplementary Table S1 ).

Currently, RM systems allow for continuous ECG recordings, as well as intermittent measurements of heart rate, blood pressure, oxygen saturation, and/or body weight. This can be performed using traditional devices (e.g. tracking vital signs and weight) or wearable technologies (e.g. smart watches, patches, and textiles). Some platforms allow patients to self-monitor their symptoms and engage with their clinician via Bluetooth and other real-time technologies. Tablet or smartphone-based platforms can integrate this data, send alerts to the HF team, and trigger a variety of clinical actions.

RM has increasingly involved data from cardiac implantable electronic devices, which can be used to monitor rhythm, hemodynamics, physiological data, and alert clinicians to early signs of HF decompensation. Perhaps the most promising strategy to date comes from implantable hemodynamic monitoring devices [3] although access to this technology is likely to remain quite limited.

It should be noted that many HFCs lack the infrastructure to support RM. It is also recognized that currently, technology enabled RM tools are not feasible for many highly vulnerable patients, including those with cognitive and/or visual impairment, frailty, limited caregiver support and limited access to (or familiarity with) internet or appbased solutions. As well, many practitioners will require up-skilling to interpret and action the data that emerges.

While a clear benefit of most RM technologies has not been established in all patients with HF, RM may be considered in those subsets who need heart rate or blood pressure assessment during titration of HF therapies, in those with tenuous hemodynamics or deemed to be at risk for decompensation, or in patients who meet indication for ambulatory vital sign or ECG monitoring. Supplementary Table S2 outlines the advantages and limitations for each consideration and the potential applicability in the Canadian context. The COVID-19 pandemic appears to have accelerated the uptake of RM technology, and may drive solutions for better workflow integration. For now, clinicians should be encouraged to marshal whatever RM resources are available in their local environment to supplement and enhance virtual HF care.

A virtual evaluation for HF as initial assessment is challenging, but not impossible, without previously establishing a clinical baseline and HF etiology. Virtual consultation between a primary care provider and specialist with secure messaging and bidirectional communication has been implemented across multiple jurisdictions in Canada and this has been expanded to include HF sub-specialty consultation as well.

This type of virtual consultation for primary care providers might be enabled by telephone support (e.g. Rapid Access to Consultative Expertise (RACE) in BC) or through a secure online platform (e.g. Building Access to Specialists through eConsultation (BASE) in Ontario). These systems could also facilitate direct-to-patient consultation, especially for low or medium-risk patients who are unattached to a HF clinician, as a broad safety-net.

Patients without established connection to a HF care provider face additional barriers to accurate diagnosis and management of symptoms; this is further amplified in the absence of a primary care provider. Many provinces have physician directories, which serve as central repositories for specialty services (e.g. Pathways in BC). These sites commonly host patient and provider resources, links for clinical decision support tools and have features to enable electronic distribution of educational materials, a key enabling strategy for virtual care.

Home care clients and long-term care residents represent a particularly vulnerable population in whom HF is common. Most Canadian provinces utilize interRAI (International Resident Assessment Instrument) standardized information systems, which can be used to identify those who require urgent HF assessment [4] .

By leveraging and strengthening existing linkages between primary care, home and community care and specialist support, we may be able to select patients who are highrisk for decompensation; thus affording an opportunity to prioritize testing and clinical review through established HFC structures and bypass the ER.

Ambulatory HF patients can be stratified into risk groups on the basis of clinical parameters, patient derived data, and objective risk scores (Supplementary Table S3 ). During the COVID-19 pandemic, it is prudent to consider an individualized approach to the provision of care based on risk assessment as well as advanced care plans. Available risk scores have reasonable predictive accuracy for mortality, however data is lacking for robust risk models related to HF hospitalization [5] .

We draw particular attention to high-risk patients with advanced HF who may be candidates for mechanical circulatory support or transplantation. It is anticipated that high-risk patients will require, at minimum, an initial in-person visit to develop a care plan; subsequent visits should be performed virtually and supported by a 'hospital in the home' approach including intravenous diuretic administration, where available. In all cases, advanced care planning is critical.

Intermediate risk patients should continue to be monitored for HF symptoms using virtual care options. Intensity and frequency should be customized and selfmanagement approaches encouraged where feasible. Medication management including diuretic titration is critical to avoiding fluid congestion.

Low risk patients should have continued access to HFC resources as needed, however routine follow-up and testing can be deferred unless there is a change in patient symptoms or status.

Crisis management through physical distancing may have unintended consequences on urgent services. Access to care is paramount for many clinical conditions, including HF, where a timeline for decompensation can be clearly articulated. As the pandemic progresses, there will be increasing pressure on the health system as those who have been 'waiting it out' at home with semi-urgent status become urgent or emergent.

As such, public health imperatives that constrain traditional HF service delivery models must be accompanied by rapid system redesign initiatives and be coupled with messaging that encourages the continued use of the health system by individuals with serious conditions, and those requiring access to highly specialized or regional services. 

The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and CCS Heart Failure Guidelines Survey

Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis

Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction

Derivation and validation of the detection of indicators and vulnerabilities for emergency room trips scale for classifying the risk of emergency department use in frail community-dwelling older adults

Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure